Clinical trials: COVID-19; Immunity
Gut Microbiota, COVID-19 Vaccine
Modulation of Gut Microbiota to Enhance Health and Immunity
The novel coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus is now a pandemic and has culminated major morbidity and mortality globally.
- Trial name
- NCT04884776
- Testing
- Microbiome immunity formula
- Where
- Hong Kong
- Volunteers
- 453 people
- Sponsor
- Chinese University of Hong Kong
End Stage Renal Disease, Kidney Transplant; Complications
COVID Vaccine Immunity in Kidney Transplant Recipients
50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled.
- Trial name
- NCT05387343
- Testing
- Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test
- Sponsor
- University of Alabama at Birmingham
COVID-19 Pandemic, SARS-CoV2 Infection
Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences
The first COVID-19 case in Turkey was reported on March 11, 2000. National COVID-19 mass vaccination was initiated on Jan 13, 202, with two doses of CoronaVac (R) inactivated vaccine (of Sinovac), 28 days apart.
- Conditions
- COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection, Health
- Trial name
- HU-CoVaCS (NCT05104385)
- Testing
- Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines
- Where
- Turkey (Türkiye)
- Volunteers
- 1,223 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
COVID 19, Respiratory Synctial Virus
COMMUNITY - the COVID-19 Immunity Study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients.
- Conditions
- COVID 19, Respiratory Synctial Virus, Influenza Virus, SARS-CoV-2 Virus
- Trial name
- COMMUNITY (NCT06784739)
- Testing
- Blood sampling, Mucosal sampling, PCR-test
- Where
- 2 sites in Sweden
- Volunteers
- 2,420 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Covid19
Convalescent Plasma for COVID-19 Research Donor Study
Convalescent Plasma for COVID-19 Research (CONCOR-Donor) study, is a national, natural history study of plasma donors recovered from COVID-19.
- Trial name
- CONCOR-Donor (NCT04555109)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- The Hospital for Sick Children
Covid 19
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and indicates that a subject is infected with SARS-CoV-2.
- Trial name
- EliSpot (NCT04418206)
- Testing
- patients COVID 19
- Where
- 4 sites in France
- Volunteers
- 950 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
COVID-19, Maternal Vaccine Exposure
Priming of the NEonatal Immune System by Transfer of Maternal Immunity
Newborn babies and infants are susceptible to infections as their immune system is still immature. Maternal immune factors for example antibodies and immune cells mitigate this vulnerability.
- Conditions
- COVID-19, Maternal Vaccine Exposure, Respiratory Infections in Children
- Trial name
- NEST (NCT05429047)
- Testing
- Tozinameran, COVID-19, No SARS-CoV-2 exposure
- Where
- Germany
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Coronavirus
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19.
- Trial name
- NCT04373148
- Testing
- There is no intervention
- Where
- 2 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Stanford University
Covid19
ImmuneRACE - Immune Response Action to COVID-19 Events
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect…
- Trial name
- NCT04494893
- Where
- United States
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
Covid19
Sex-Informed Data in the COVID-19 Pandemic.
Sex and gender matter to health equity, especially in a pandemic. Sex (a biological attribute) and gender (a social construct) may influence an individual's susceptibility, vulnerability and exposure to infectious disease.
- Trial name
- G-COV (NCT04497402)
- Where
- Italy
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Kidney Transplant Recipient
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
The purpose of this research is to see if a dose of the Janssen Ad26.CoV2.S vaccine effects the immune protection in individuals who have had a kidney transplant and two or three doses of mRNA vaccine (Pfizer and/or Moderna…
- Trial name
- NCT05220397
- Testing
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Where
- 3 sites in United States
- Volunteers
- 468 people
- Sponsor
- Mark Stegall
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT04852822
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 11 sites in United States
- Volunteers
- 350 people
- Sponsor
- University of Washington
SARS-CoV 2
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies.
- Trial name
- AcNT-COVID19 (NCT04596098)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Grenoble
Liver Transplant Infection, Covid19
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective…
- Conditions
- Liver Transplant Infection, Covid19, Mortality, Immune Response
- Trial name
- NCT04410471
- Testing
- CLIA of IgG and IgM against SARS-Cov-2
- Where
- 2 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Magdalena Salcedo
COVID-19, Vaccine Reaction
Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora
The elderly, who are often in poorer health, have been particularly affected by the COVID-19 pandemic. Recent study results show that while vaccines have been very effective in the short term, protection for the elderly may not…
- Conditions
- COVID-19, Vaccine Reaction, Elderly
- Trial name
- PIRATES-COV (NCT05195151)
- Where
- Canada
- Volunteers
- 592 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
SARS-COV-2
Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences
A previous seroprevalence survey showed very high seroprevalence levels among residents of the two among the residents of the two migrant workers' hostels surveyed, indicating a high level of circulation of the virus SARS-COV-2…
- Trial name
- NCT04932837
- Testing
- Blood and Saliva collection
- Where
- 2 sites in France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Epicentre
COVID-19, Immunity
Understanding Immunity to the COVID-19 Vaccines
The purpose of this study is to test over time immunity to the COVID-19 vaccines. Adults who are receiving COVID-19 vaccines will be invited to participate.
- Conditions
- COVID-19, Immunity, Vaccine
- Trial name
- NCT04664309
- Testing
- No intervention
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Stanford University
Covid19, SARS-CoV Infection
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
SARS-CoV-2 is a member of a class of viruses: angiotensin converting enzyme 2 (ACE2)-binding viruses that study calls "ABVs". The World Health Organization (WHO) and others are performing randomized controlled trials (RCTs) of…
- Trial name
- ARBs CORONA II (NCT04606563)
- Testing
- Losartan, Valsartan, Azilsartan
- Where
- 13 sites in Canada, France
- Volunteers
- 341 people
- Sponsor
- University of British Columbia
COVID-19
Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand
The investigators assessed the effect of treatment for COVID and immunity of the volunteers who admitted to the home isolation.
- Trial name
- NCT05328479
- Where
- Thailand
- Volunteers
- 5,181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
SARS-CoV-2 Infection
Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)
SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune responses.
- Trial name
- COV-CREM (NCT04365322)
- Testing
- Additional biological samples
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon